Preclinical data suggested that tafasitamab might act synergistically with lenalidomide. We aimed to assess the antitumour activity and safety of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma who …

2020年7月31日，美国食品和药物管理局（FDA）首次批准了 Tafasitamab （商品名 MONJUVI®），与 来那度胺 联合应用，用于治疗成人复发或难治性弥漫性大B细胞淋巴瘤（DLBCL），包括低度淋巴瘤引起的DLBCL，以及不符合自体干细胞移植（ASCT）条件的患者。

Tafasitamab (tafa), a humanized CD19-targeting monoclonal antibody (mAb), induces direct cytotoxicity and enhances NK cell and macrophage immune-mediated mechanisms.

Tafasitamab (TAFA) in combination with lenalidomide (LEN) is approved for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

2022年6月2日 · Tafasitamab (TAFA) is an Fc-engineered humanized monoclonal antibody (mAb) against CD19 which is broadly expressed in FL and MZL, and regulates B-cell proliferation via B-cell receptor signaling. In preclinical studies, TAFA has shown activity against NHL cell lines in combination with rituximab (anti-CD20 mAb) and lenalidomide (LEN).

2020年6月5日 · Tafasitamab in combination with lenalidomide was well tolerated and resulted in a high proportion of patients with relapsed or refractory diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation having a complete response, and might represent a new therapeutic option in this setting.

2024年11月5日 · Introduction: Tafa is a CD19-targeting immunotherapy indicated in combination with lenalidomide (len) for the treatment of R/R DLBCL in adult patients (pts) ineligible for autologous stem cell transplantation. To date, few studies have examined tafa in a US real-world setting, especially from a community practice perspective.

2022年6月9日 · Tafasitamab 是一款靶向CD19的Fc结构域优化的人源化 单克隆抗体。 Tafasitamab 联合来那度胺已获海南省卫健委和药监局批准，在海南博鳌乐城国际医疗旅游先行区用于治疗符合条件的复发或难治性 DLBCL患者，目前尚未获得中国药监局批准用于任何适应症。 Tafasitamab和来那度胺联合疗法已经获得美国食品药品监督管理局（FDA）以及欧洲药品管理局（EMA）有条件批准，用于治疗不适合自体干细胞移植条件的复发或难治性DLBCL患者。 (医 …

2023年9月28日 · tafasitamab（Tafa）是一种靶向CD19的单克隆抗体的药物，它可以通过抗体介导的细胞毒性作用，以及抗体介导的吞噬作用，也就是ADCC和ADCP的作用，通过细胞凋亡和免疫效应机制介导B细胞肿瘤的裂解。 Tafa主要适合一部分复发难治的弥漫性大B细胞淋巴瘤患者。 尤其临床上年龄大，或者因为各种原因，暂时没有办法进行自体造血干细胞移植，这部分患者用Tafa这一类的药物联合来那度胺使用。 最关键的临床数据源于一项国际的多中心的单臂的Ⅱ …

2022年11月15日 · Background: TAFA is a CD19-directed monoclonal antibody approved in combination with LEN for the treatment of adult patients with R/R DLBCL who are not eligible for transplant. As the number of available CD19-directed therapies, including CAR-T, for patients with DLBCL increase, the optimal sequencing of such therapies needs to be established.